ANI Pharmaceuticals Inc (ANIP) stock
Close on Nov 17, 2026Market cap $1.61BP/E 14.9Yield –
Earnings
ANI Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of ANI Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 26, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026before the open | $290.80M | +27.7% | $1.51 | $2.70 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 7, 2026before the open | $266.00M | +25.8% | $1.05 | $2.21 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 8, 2026before the open | $237.50M | +20.5% | $1.28 | $2.05 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 27, 2026before the open | $247.10M | +29.6% | $1.18 | $2.33 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 7, 2025before the open | $227.80M | +53.6% | $1.13 | $2.04 | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 8, 2025before the open | $211.40M | +53.2% | $0.36 | $1.80 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 9, 2025before the open | $197.10M | +43.4% | $0.69 | $1.70 | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 28, 2025before the open | $190.60M | +44.7% | -$0.55 | $1.63 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 8, 2024before the open | $148.30M | +12.5% | -$1.27 | $1.34 | Release |
| Q2 FY2024ended Jun 30, 2024 | Aug 6, 2024before the open | $138.00M | +18.5% | -$0.14 | $1.02 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 10, 2024before the open | $137.40M | +28.7% | $0.82 | $1.21 | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 29, 2024before the open | $131.70M | +39.8% | $0.04 | $1.00 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 8, 2023before the open | $131.80M | +57.3% | $0.45 | $1.27 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 9, 2023before the open | $116.50M | +57.6% | $0.29 | $1.28 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 8, 2023before the open | $106.80M | +65.6% | $0.06 | $1.17 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 9, 2023before the open | $94.20M | +54.7% | -$0.28 | $0.76 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 9, 2022during market hours | $83.80M | +60.8% | -$0.55 | $0.64 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 8, 2022before the open | $73.90M | – | -$0.94 | $0.13 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022before the open | $64.50M | – | -$1.27 | -$0.12 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 15, 2022before the open | $60.90M | – | -$1.72 | $0.54 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 1, 2021before the open | $52.10M | – | -$0.37 | $1.01 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 6, 2021before the open | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 7, 2021before the open | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 9, 2021before the open | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 5, 2020before the open | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
ANI Pharmaceuticals's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| Cortrophin Gel net revenue growth | FY2026 | +50% – +55% | – | Raised | Aug 7, 2026 |
| ILUVIEN Net Revenue | FY2026 | $80.00M – $85.00M | $540.00M – $575.00M | Lowered | Nov 5, 2026 |
| total net revenue | FY2026 | $1.08B – $1.14B | $1.08B – $1.14B | Reaffirmed | Aug 7, 2026 |
| adjusted non-GAAP gross marginnon-GAAP | FY2026 | 59.9% – 60.9% | 59.9% – 60.9% | Reaffirmed | Aug 7, 2026 |
| total company adjusted non-GAAP gross marginnon-GAAP | FY2026 | 60.3% – 61% | 59.3% – 60.3% | Raised | Nov 5, 2026 |
| adjusted non-GAAP EBITDAnon-GAAP | FY2026 | $285.00M – $300.00M | $285.00M – $300.00M | Reaffirmed | Aug 7, 2026 |
| Adjusted Non-GAAP EBITDAnon-GAAP | FY2026 | $290.00M – $300.00M | $275.00M – $290.00M | Raised | Nov 5, 2026 |
| Adjusted Non-GAAP EBITDA Growthnon-GAAP | FY2026 | +24% – +31% | – | New | Aug 7, 2026 |
| Adjusted Non-GAAP Diluted EPSnon-GAAP | FY2026 | $9.37 – $9.71 | $8.83 – $9.34 | Raised | Nov 5, 2026 |
| Adjusted Non-GAAP Diluted EPSnon-GAAP | FY2026 | $9.19 – $9.69 | $9.19 – $9.69 | Reaffirmed | Aug 7, 2026 |
| Adjusted Non-GAAP Diluted EPS Growthnon-GAAP | FY2026 | +16% – +23% | – | New | Aug 7, 2026 |
| annual U.S. GAAP effective tax rateGAAP | FY2026 | 26% – 28% | 26% – 28% | Reaffirmed | Aug 7, 2026 |
| annual U.S. GAAP effective tax rateGAAP | FY2026 | 26% – 28% | – | New | Feb 27, 2026 |
| Cortrophin Gel net revenue | FY2026 | $540.00M – $575.00M | – | New | May 8, 2026 |
| ILUVIEN Net Revenue | FY2026 | $78.00M – $83.00M | – | Lowered | May 8, 2026 |
| shares outstandingnon-GAAP | FY2026 | 21.5 – 21.8 | – | New | May 8, 2026 |
| shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPSnon-GAAP | FY2026 | 21.5 – 21.8 | – | Reaffirmed | Aug 7, 2026 |
Guidance vs results
The last range ANI Pharmaceuticals gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | adjusted non-GAAP diluted earnings per share | $7.37 – $7.64 | $7.87Σ4Q | Above range |
| FY2025 | Revenue | $73.00M – $77.00M | $883.40MΣ4Q | Above range |
| FY2025 | Revenue growth | +75% – +78% | +43.81%Σ4Q | Below range |
Guidance history
Every forecast ANI Pharmaceuticals put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | Adjusted Non-GAAP EBITDA | FY2026 | $290.00M – $300.00M | Raised |
| Nov 5, 2026 | Adjusted Non-GAAP Diluted EPS | FY2026 | $9.37 – $9.71 | Raised |
| Nov 5, 2026 | total company adjusted non-GAAP gross margin | FY2026 | 60.3% – 61% | Raised |
| Nov 5, 2026 | ILUVIEN Net Revenue | FY2026 | $80.00M – $85.00M | Lowered |
| Nov 5, 2026 | Cortrophin Gel Net Revenue | FY2026 | $480.00M – $500.00M | Lowered |
| Nov 5, 2026 | Net Revenue (Total Company) | FY2026 | $1.09B – $1.13B | Raised |
| Aug 7, 2026 | Adjusted Non-GAAP EBITDA Growth | FY2026 | +24% – +31% | New |
| Aug 7, 2026 | adjusted non-GAAP EBITDA | FY2026 | $285.00M – $300.00M | Reaffirmed |
| Aug 7, 2026 | Adjusted Non-GAAP Diluted EPS | FY2026 | $9.19 – $9.69 | Reaffirmed |
| Aug 7, 2026 | Adjusted Non-GAAP Diluted EPS Growth | FY2026 | +16% – +23% | New |
| Aug 7, 2026 | adjusted non-GAAP gross margin | FY2026 | 59.9% – 60.9% | Reaffirmed |
| Aug 7, 2026 | shares outstanding for the purpose of calculating full year adjusted non-GAAP diluted EPS | FY2026 | 21.5 – 21.8 | Reaffirmed |
| Aug 7, 2026 | annual U.S. GAAP effective tax rate | FY2026 | 26% – 28% | Reaffirmed |
| Aug 7, 2026 | Cortrophin Gel net revenue growth | FY2026 | +50% – +55% | Raised |
| Aug 7, 2026 | ILUVIEN Net Revenue Growth | FY2026 | +4% – +11% | Lowered |
| Aug 7, 2026 | total net revenue | FY2026 | $1.08B – $1.14B | Reaffirmed |
| Aug 7, 2026 | Cortrophin Gel net revenue | FY2026 | $520.00M – $540.00M | Lowered |
| Aug 7, 2026 | ILUVIEN Net Revenue | FY2026 | $78.00M – $83.00M | Lowered |
| Aug 7, 2026 | Net Revenue (Total Company) Growth | FY2026 | +22% – +29% | New |
| May 8, 2026 | adjusted non-GAAP EBITDA | FY2026 | $285.00M – $300.00M | Raised |
| May 8, 2026 | adjusted non-GAAP diluted earnings per share | FY2026 | $9.19 – $9.69 | Raised |
| May 8, 2026 | adjusted non-GAAP gross margin | FY2026 | 59.9% – 60.9% | Raised |
| May 8, 2026 | ILUVIEN Net Revenue | FY2026 | $78.00M – $83.00M | Lowered |
| May 8, 2026 | shares outstanding | FY2026 | 21.5 – 21.8 | New |
| May 8, 2026 | annual U.S. GAAP effective tax rate | FY2026 | 26% – 28% | Reaffirmed |
| May 8, 2026 | Cortrophin Gel net revenue | FY2026 | $540.00M – $575.00M | New |
| May 8, 2026 | total net revenue | FY2026 | $1.08B – $1.14B | Raised |
| Feb 27, 2026 | Adjusted Non-GAAP EBITDA | FY2026 | $275.00M – $290.00M | New |
| Feb 27, 2026 | Adjusted Non-GAAP Diluted EPS | FY2026 | $8.83 – $9.34 | New |
| Feb 27, 2026 | adjusted non-GAAP gross margin | FY2026 | 59.3% – 60.3% | New |
| Feb 27, 2026 | annual U.S. GAAP effective tax rate | FY2026 | 26% – 28% | New |
| Feb 27, 2026 | Cortrophin Gel Net Revenue | FY2026 | $540.00M – $575.00M | Lowered |
| Feb 27, 2026 | Net Revenue (Total Company) | FY2026 | $1.06B – $1.12B | New |
| Feb 27, 2026 | ILUVIEN Net Revenue | FY2026 | $78.00M – $83.00M | Lowered |
| Jan 12, 2026 | Adjusted non-GAAP EBITDA | FY2026 | $275.00M – $290.00M | New |
| Jan 12, 2026 | Adjusted Non-GAAP Diluted EPS | FY2026 | $8.83 – $9.34 | New |
| Jan 12, 2026 | adjusted non-GAAP gross margin | FY2026 | 59.3% – 60.3% | New |
| Jan 12, 2026 | annual U.S. GAAP effective tax rate | FY2026 | 26% – 28% | New |
| Jan 12, 2026 | Total net revenues | FY2026 | $1.06B – $1.12B | New |
| Nov 7, 2025 | adjusted non-GAAP EBITDA | FY2025 | $221.00M – $228.00M | New |
| Nov 7, 2025 | adjusted non-GAAP diluted earnings per share | FY2025 | $7.37 – $7.64 | New |
| Nov 7, 2025 | adjusted non-GAAP gross margin | FY2025 | 61% – 62% | New |
| Nov 7, 2025 | Purified Cortrophin Gel net revenues year-over-year growth | FY2025 | +75% – +78% | New |
| Nov 7, 2025 | ILUVIEN (1) net revenues | FY2025 | $73.00M – $77.00M | Lowered |
| Nov 7, 2025 | Purified Cortrophin Gel net revenues | FY2025 | $347.00M – $352.00M | Lowered |
| Nov 7, 2025 | total net revenue | FY2025 | $854.00M – $873.00M | New |
| Aug 8, 2025 | adjusted non-GAAP EBITDA | FY2025 | $213.00M – $223.00M | Raised |
| Aug 8, 2025 | adjusted non-GAAP diluted earnings per share | FY2025 | $6.98 – $7.35 | Raised |
| Aug 8, 2025 | adjusted non-GAAP gross margin | FY2025 | 63% – 64% | Reaffirmed |
| Aug 8, 2025 | net revenues | FY2025 | $818.00M – $843.00M | Raised |
| May 9, 2025 | adjusted non-GAAP EBITDA | FY2025 | $195.00M – $205.00M | Raised |
| May 9, 2025 | adjusted non-GAAP diluted earnings per share | FY2025 | $6.27 – $6.62 | Raised |
| May 9, 2025 | total company adjusted non-GAAP gross margin | FY2025 | 63% – 64% | Reaffirmed |
| May 9, 2025 | Rare Disease net revenues expected to represent of total Company net revenues | FY2025 | 47% – 48% | New |
| May 9, 2025 | annual U.S. GAAP effective tax rate | FY2025 | 25% | New |
| May 9, 2025 | ILUVIEN and YUTIQ net revenues | FY2025 | $97.00M – $103.00M | Lowered |
| May 9, 2025 | net revenues | FY2025 | $768.00M – $793.00M | Raised |
| May 9, 2025 | Purified Cortrophin Gel net revenues year-over-year growth | FY2025 | +33.8% – +38.3% | Raised |
| May 9, 2025 | Purified Cortrophin Gel net revenues | FY2025 | $265.00M – $274.00M | Lowered |
| Feb 28, 2025 | adjusted non-GAAP EBITDA | FY2025 | $190.00M – $200.00M | Raised |
| Feb 28, 2025 | adjusted non-GAAP diluted earnings per share | FY2025 | $6.12 – $6.49 | New |
| Feb 28, 2025 | adjusted non-GAAP gross margin | FY2025 | 63% – 64% | New |
| Feb 28, 2025 | net revenues | FY2025 | $756.00M – $776.00M | Raised |
| Jan 13, 2025 | adjusted non-GAAP EBITDA | FY2025 | $182.00M – $192.00M | New |
| Jan 13, 2025 | total net revenues | FY2025 | $739.00M – $759.00M | New |
| Jan 13, 2025 | growth | FY2025 | +24% – +27% | New |
| Nov 8, 2024 | adjusted non-GAAP EBITDA | FY2024 | $149.00M – $153.00M | Raised |
| Nov 8, 2024 | adjusted non-GAAP earnings per share | FY2024 | $4.90 – $5.05 | Raised |
| Nov 8, 2024 | total company adjusted non-GAAP gross margin | FY2024 | 62% | Raised |
| Nov 8, 2024 | Purified Cortrophin Gel net revenues year-over-year growth | FY2024 | +75% – +78% | New |
| Nov 8, 2024 | ILUVIEN and YUTIQ net revenues | FY2024 | $30.00M – $32.00M | Lowered |
| Nov 8, 2024 | net revenues | FY2024 | $594.00M – $602.00M | Raised |
| Nov 8, 2024 | Purified Cortrophin Gel net revenues | FY2024 | $196.00M – $200.00M | Lowered |
| Aug 6, 2024 | adjusted non-GAAP EBITDA | FY2024 | $140.00M – $150.00M | Raised |
| Aug 6, 2024 | adjusted non-GAAP earnings per share | FY2024 | $4.38 – $4.82 | Raised |
| Aug 6, 2024 | total company adjusted non-GAAP gross margin | FY2024 | 61% – 62% | Lowered |
| Aug 6, 2024 | expected net revenues | FY2024 | $540.00M – $560.00M | Raised |
| May 10, 2024 | adjusted non-GAAP EBITDA | FY2024 | $135.00M – $145.00M | Reaffirmed |
| May 10, 2024 | adjusted non-GAAP earnings per share | FY2024 | $4.26 – $4.67 | Reaffirmed |
| May 10, 2024 | total company adjusted non-GAAP gross margin | FY2024 | 62% – 63% | Reaffirmed |
| May 10, 2024 | shares outstanding | FY2024 | 19.4 – 19.7 | Raised |
| May 10, 2024 | U.S. GAAP effective tax rate | FY2024 | 22% – 25% | Raised |
| May 10, 2024 | tax rate | FY2024 | 26% | Reaffirmed |
| May 10, 2024 | Cortrophin Gel net revenues | FY2024 | $170.00M – $180.00M | Reaffirmed |
| May 10, 2024 | net revenues | FY2024 | $520.00M – $542.00M | Reaffirmed |
| Feb 29, 2024 | adjusted non-GAAP EBITDA | FY2024 | $135.00M – $145.00M | New |
| Feb 29, 2024 | adjusted non-GAAP earnings per share | FY2024 | $4.26 – $4.67 | New |
| Feb 29, 2024 | total company adjusted non-GAAP gross margin | FY2024 | 62% – 63% | New |
| Feb 29, 2024 | shares outstanding | FY2024 | 19.3 – 19.7 | New |
| Feb 29, 2024 | U.S. GAAP effective tax rate | FY2024 | 20% – 22% | New |
| Feb 29, 2024 | tax rate | FY2024 | 26% | New |
| Feb 29, 2024 | Purified Cortrophin ® Gel (Repository Corticotrophin Injection USP) 80 U/ml (Cortrophin Gel) net revenues | FY2024 | $170.00M – $180.00M | New |
| Feb 29, 2024 | net revenues | FY2024 | $520.00M – $542.00M | New |
| Nov 8, 2023 | adjusted non-GAAP EBITDA | FY2023 | $128.00M – $133.00M | Raised |
| Nov 8, 2023 | adjusted non-GAAP earnings per share | FY2023 | $4.29 – $4.57 | Raised |
| Nov 8, 2023 | Adj. Non-GAAP Gross Margin | FY2023 | 63% – 63.8% | Raised |
| Nov 8, 2023 | net revenue | FY2023 | $468.00M – $478.00M | Raised |
| Aug 9, 2023 | adjusted non-GAAP EBITDA | FY2023 | $115.00M – $125.00M | Raised |
| Aug 9, 2023 | adjusted non-GAAP earnings per share | FY2023 | $3.62 – $4.11 | Raised |
| Aug 9, 2023 | shares outstanding | FY2023 | 19.1 – 19.3 | New |
| Aug 9, 2023 | U.S. GAAP effective tax rate | FY2023 | 6% – 10% | New |
| Aug 9, 2023 | Cortrophin Gel specific revenue | FY2023 | $90.00M – $100.00M | New |
| Aug 9, 2023 | net revenue | FY2023 | $425.00M – $445.00M | Raised |
| May 8, 2023 | total Company adjusted non-GAAP EBITDA | FY2023 | $97.00M – $107.00M | Raised |
| May 8, 2023 | adjusted non-GAAP diluted earnings per share | FY2023 | $2.99 – $3.45 | Raised |
| May 8, 2023 | Total Company non-GAAP gross margin | FY2023 | 60% – 62.5% | Raised |
| May 8, 2023 | total Company net revenue | FY2023 | $385.00M – $410.00M | Raised |
| Mar 9, 2023 | Total Company Adjusted non-GAAP EBITDA | FY2023 | $78.00M – $88.00M | New |
| Mar 9, 2023 | Adjusted non-GAAP Diluted Earnings per Share | FY2023 | $2.09 – $2.59 | New |
| Mar 9, 2023 | Total Company non-GAAP Gross Margin | FY2023 | 59.5% – 61% | New |
| Mar 9, 2023 | Total Company expected Net Revenues | FY2023 | $360.00M – $385.00M | New |
| Nov 9, 2022 | Adjusted non-GAAP EBITDA | FY2022 | $54.00M – $60.00M | Reaffirmed |
| Nov 9, 2022 | Adjusted non-GAAP Diluted Earnings per Share | FY2022 | $1.34 – $1.62 | Reaffirmed |
| Nov 9, 2022 | Net Revenue | FY2022 | $295.00M – $315.00M | Reaffirmed |
| Aug 8, 2022 | Adjusted non-GAAP EBITDA | FY2022 | $54.00M – $60.00M | Reaffirmed |
| Aug 8, 2022 | Adjusted non-GAAP Diluted Earnings per Share | FY2022 | $1.34 – $1.62 | Reaffirmed |
| Aug 8, 2022 | shares outstanding | FY2022 | 16.9 – 17 | Lowered |
| Aug 8, 2022 | effective tax rate | FY2022 | 24% | Reaffirmed |
| Aug 8, 2022 | Research and Development expense | FY2022 | $16.00M – $18.00M | Reaffirmed |
| Aug 8, 2022 | Revised Net Revenue | FY2022 | $40.00M – $45.00M | Raised |
| Aug 8, 2022 | Direct Selling, General and Administrative expenses | FY2022 | $42.00M – $46.00M | Raised |
| Aug 8, 2022 | Net Revenue | FY2022 | $295.00M – $315.00M | Reaffirmed |
| May 10, 2022 | Adjusted non-GAAP EBITDA | FY2022 | $54.00M – $60.00M | Lowered |
| May 10, 2022 | Adjusted non-GAAP Diluted Earnings per Share | FY2022 | $1.34 – $1.62 | New |
| May 10, 2022 | Research and Development expense | FY2022 | $16.00M – $18.00M | Lowered |
| May 10, 2022 | Net Revenue | FY2022 | $295.00M – $315.00M | Raised |
| Mar 15, 2022 | Adjusted non-GAAP EBITDA | FY2022 | $70.00M – $75.00M | New |
| Mar 15, 2022 | shares outstanding | FY2022 | 16.9 – 17.3 | New |
| Mar 15, 2022 | effective tax rate | FY2022 | 24% | New |
| Mar 15, 2022 | Research and Development expense | FY2022 | $16.00M – $18.00M | New |
| Mar 15, 2022 | Direct Selling, General and Administrative expenses | FY2022 | $42.00M – $46.00M | Raised |
| Mar 15, 2022 | Net Revenues | FY2022 | $260.00M – $275.00M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases ANI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- News
- News
- News
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Results
- Results
- Update
See a number that looks wrong?